Physician

Mohammad Arshad Bashir, MD

According to 2025 Medicare claims, Mohammad Bashir, MD (NPI: 1659306843) practices internal medicine in the Saginaw, MI market, with the plurality of this provider's patient population coming from Saginaw, MI. This provider's primary affiliated billing organization is DIALYSIS ASSOCIATES, P.C. (NPI: 1467549618; TIN: 382354912) and primary practice location at 48604-2839. Bashir is affiliated with the POM ACO (ACO ID: A1297), McLaren High Performance Network, LLC (ACO ID: A3317), and Mosaic ACO (ACO ID: A5033), participating under the MSSP model.

Bashir's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 264 traditional Medicare patients, billed 1,176 HCPCS/CPT codes, and received $157,769 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 1,669 prescription claims across 300 beneficiaries totaling $327,748 in drug costs, led by Jardiance (Empagliflozin). DME data shows 294 claims. Open Payments data shows 10 records totaling $244. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $296,894 to $157,769. Similarly, Part D prescription costs have moved from a higher plateau to a lower plateau, from $507,345 to $327,748. In contrast, DME billing represents a smaller volume and changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	597	4,114	$296,894
2016	567	3,173	$278,944
2017	530	2,626	$283,097
2018	556	2,349	$269,658
2019	530	2,447	$260,850
2020	367	1,845	$210,753
2021	380	1,841	$211,151
2022	277	1,344	$161,159
2023	288	1,214	$152,267
2024	264	1,176	$157,769

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	244	1,370	$507,345
2016	241	1,333	$457,361
2017	253	1,394	$536,081
2018	285	1,462	$354,280
2019	256	1,312	$282,765
2020	213	1,128	$181,254
2021	232	1,194	$219,013
2022	229	1,100	$201,226
2023	254	1,274	$270,395
2024	300	1,669	$327,748

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	23	311	$27,411
2016	11	191	$11,609
2017	N/R	185	$10,460
2018	N/R	184	$12,760
2019	N/R	225	$14,480
2020	N/R	102	$7,497
2021	N/R	97	$1,639
2022	N/R	143	$4,430
2023	N/R	212	$6,720
2024	N/R	294	$5,893

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	32	247	$278
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	54	64	$134
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	104	243	$90
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	116	337	$60
90935	Hemodialysis procedure with physician evaluation	33	57	$55

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jardiance	Empagliflozin	63	5,070	$92,843
Lokelma	Sodium Zirconium Cyclosilicate	52	2,851	$61,185
Ozempic	Semaglutide	13	728	$22,877
Lanthanum Carbonate	Lanthanum Carbonate	25	750	$22,394
Epogen	Epoetin Alfa	12	790	$14,460

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	34	$1,588
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	73	$1,380
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	86	$1,229
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	59	$1,073
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	23	$613

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	10	$244	Travere Therapeutics, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mohammad Arshad Bashir, MD?

Tedicare shows public-source Medicare data for Mohammad Arshad Bashir, MD (NPI 1659306843), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mohammad Arshad Bashir, MD have ACO affiliation data?

Mohammad Arshad Bashir, MD is shown with ACO affiliation data for POM ACO (MSSP, ACO ID A1297), McLaren High Performance Network, LLC (MSSP, ACO ID A3317), and Mosaic ACO (MSSP, ACO ID A5033).

What billing organization is linked to Mohammad Arshad Bashir, MD?

Mohammad Arshad Bashir, MD is linked to DIALYSIS ASSOCIATES, P.C. (billing NPI 1467549618) in the available physician profile data.

Does Mohammad Arshad Bashir, MD have Open Payments data?

Mohammad Arshad Bashir, MD has 10 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.